<DOC>
	<DOCNO>NCT00006877</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy temozolomide term complete partial response rate patient metastatic non-small cell lung cancer . II . Determine safety regimen patient . III . Determine time progression overall survival patient treat regimen . IV . Determine quality life change disease-related symptom patient treated regimen . OUTLINE : This multicenter study . Patients receive oral temozolomide daily day 1-7 15-21 . Treatment continue every 4 week maximum 6 month absence disease progression unacceptable toxicity . Quality life assess baseline , every 4 week study , every 8 week study . Patients follow 1 month every 8 week thereafter . PROJECTED ACCRUAL : A total 15-60 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic nonsmall cell lung cancer Eligible subtypes : Adenocarcinoma Squamous cell carcinoma Large cell carcinoma At least 1 bidimensionally measurable lesion , least 2 cm 2 cm perpendicular diameter radiologic study Previously irradiate bony lesion consider measurable unless evidence disease progression site prior study No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN ( 5 time ULN document liver metastasis ) Alkaline phosphatase great 2 time ULN ( 5 time ULN document liver metastasis ) Renal : Blood urea nitrogen great 1.5 time ULN Creatinine great 1.5 time ULN Other : No active nonmalignant systemic disease would increase risk No frequent vomit medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) No malignancy within past 5 year except surgically cure carcinoma situ cervix basal cell squamous cell skin cancer HIV negative No AIDSrelated illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy biologic therapy No concurrent growth factor epoetin alfa Chemotherapy : At least 4 week since prior chemotherapy No 1 prior chemotherapy regimen metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Prior radiotherapy local control palliative therapy painful bony lesion allow No prior radiotherapy 50 % bone marrow At least 4 week since prior radiotherapy 15 % bone marrow ( 2 week radiotherapy less 15 % bone marrow ) recover No concurrent radiotherapy Surgery : Not specify Other : Recovered prior therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>